Table 1. Patient, tumour, and treatment characteristics.
| Patient /Tumour | Age (years) | TNM Stage* | Molecular subtypes | Prior breast surgery | Prior breast radiotherapy | Immediate prior systemic therapy | Treatment site | RT Dose | RT Technique | Number of MRgFUS +MB Treatments | Number of US cells | FUS power (watts) | Duration of each MRgFUS+MB treatment (min) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| #1 | 72 | T4N2M1 | Basal-like | BCS | None | None | Left breast | 40 Gy/10 Fx | 3D-CRT | 2 | 3 | 4 | 66 and 59 |
| #2 Left | 75 | T3N2M1 | HR+ HER2- | BCS | Yes, unknown details | Palbociclib, Letrozole | Right breast | 30 Gy/5 Fx | 3D-CRT | 2 | 3 | 7 | 63 and 39 |
| #2 Right | 75 | T3N2M1 | HR+ HER2- | BCS | Yes, unknown details | Palbociclib, Letrozole | Left breast | 30 Gy/5 Fx | 3D-CRT | 2 | 3 | 4 | 49 and 45 |
| #3 | 59 | T4N2M1 | HR- HER2+ | Mastectomy | None | TDM1 | Right chest wall | 30 Gy/5 Fx | IMRT | 2 | 4 | 6 | 70 and 65 |
| #4 | 44 | T3N1M0 | Basal-like | BCS | None | None | Right breast | 30 Gy/10 Fx | 3D-CRT | 2 | 6 | 4 | 92 and 82 |
| #5 | 59 | T3N2M1 | HR+ HER2- | None | None | None | Left breast | 20 Gy/5Fx | 3D-CRT | 2 | 3 | 8 | 77 and 61 |
| #6 | 76 | T4N2M1 | HR+ HER2- | BCS | 50 Gy/25 Fx | Capecitabine | Left breast | 20 Gy/5Fx | 3D-CRT | 2 | 5 | 5 | 96 and 88 |
| #7 | 57 | T4N2M1 | HR+ HER2+ | None | None | Trastuzumab | Left breast skin nodules | 40 Gy/10 Fx | 3D-CRT | 2 | 7 | 4 | 89 and 61 |
| #8 | 61 | T3N2M1 | Basal-like | Mastectomy | 50 Gy/25 Fx | Gemcitabine, Carboplatin | Left chest wall | 20 Gy/5Fx | 3D-CRT | 2 | 8 | 4 | 112 and 122 |
| #9 | 51 | T4N3M1 | HR+ HER2- | BCS | 50 Gy/25 Fx | Capecitabine | Left breast skin nodules | 20 Gy/5Fx | Electrons | 2 | 4 | 3 | 60 and 60 |
| #10 | 74 | T4N2M1 | HR+ HER2- | None | None | Palbociclib, Letrozole | Left breast | 35 Gy/5 Fx | 3D-CRT | 2 | 8 | 6 | 120 and 101 |
| #11 | 67 | T3N0M0 | HR+ HER2- | Mastectomy | 50 Gy/25 Fx; 42.6Gy/16 Fx | Fulvest, Palbociclib | Left breast skin nodules | 20 Gy/5 Fx | Electrons | 2 | 3 | 3 | 49 and 45 |
| #12 | 60 | T2N3M1 | HR+ HER2+ | Mastectomy | None | TDM1 | Right chestwall | 20 Gy/5 Fx | IMRT | 2 | 5 | 4 | 78 and 62 |
| #13 | 56 | T3N1M1 | HR- HER2+ | None | None | Pertuzumab, Trastuzumab | Right breast | 35 Gy/5 Fx | IMRT | 2 | 6 | 4 | 91 and 71 |
| #14 Left | 44 | T4N3M1 | HR+ HER2+ | None | None | Pertuzumab, Trastuzumab | Left breast | 66 Gy/33 Fx | 3D-CRT | 3 | 6 | 4 | 60, 70 and 70 |
| #14 Right | 44 | T4N3M1 | HR+ HER2+ | None | None | Pertuzumab, Trastuzumab | Right breast | 66 Gy/33 Fx | 3D-CRT | 3 | 6 | 4 | 70, 70 and 60 |
| #15 | 88 | T2N1M1 | HR+ HER2- | Lumpectomy | 20 Gy/5 Fx | Letrozol | Left breast | 20 Gy/5 Fx | 3D-CRT | 2 | 5 | 4 | 65 and 60 |
| #16 | 63 | T2N1M1 | HR+ HER2— | Lumpectomy | 42.6Gy/16 Fx | Anastrozole | Right chest wall | 35 Gy/5 Fx | IMRT | 2 | 2 | 4 | 45 and 34 |
| #17 | 50 | T3N1M1 | HR+ HER2- | None | 25 Gy/15 Fx | Letrozole, Ribociclib. | Left breast | 20 Gy/5 Fx | 3D-CRT | 2 | 8 | 5 | 90 and 90 |
| #18 | 90 | T2N1M1 | HR+ HER2- | None | None | Letrozol | Right breast | 35 Gy/5 Fx | IMRT | 2 | 7 | 5 | 95 and 100 |
* TNM Stage per the 8th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual [25].
BCS, breast-conserving surgery; 3D-CRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; HR, hormone-receptor; HER2, human epidermal growth factor receptor 2; MRgFUS-MB, magnetic resonance-guided focussed ultrasound-stimulated microbubble; FUS, focused ultrasound; min, minutes.